This page lists the gynaecology hospitals in our directory offering Ovarian Transposition Surgery in Bengaluru, India, including Narayana Health, Manipal Hospitals, Medicover Hospital, Bangalore, Gleneagles Hospitals, Bengaluru and others. Each listing links through to the hospital's full profile page.
Ask us about ovarian transposition surgery in Bengaluru, India
Share a few details and our care coordination team will get back to you with next steps.
Compare 10 accredited hospitals for Gynaecology in Bengaluru, India
Featured🇮🇳 Narayana Health
Ranks #1 in this list by listed rating (4.8/5 from 1750 reviews).
🇮🇳 Manipal Hospitals
Ranks #2 in this list by listed rating (4.7/5 from 1450 reviews).
🇮🇳 Medicover Hospital, Bangalore
Ranks #3 in this list by listed rating (4.7/5 from 68 reviews).
🇮🇳 Gleneagles Hospitals, Bengaluru
Ranks #4 in this list by listed rating (4.7/5 from 142 reviews).
🇮🇳 Manipal Hospital Malleshwaram (Northside)
Ranks #5 in this list by listed rating (4.6/5 from 71 reviews).
🇮🇳 Manipal Hospital, Old Airport Road
Ranks #6 in this list by listed rating (4.5/5 from 87 reviews).
🇮🇳 Manipal Hospital Yeshwanthpur (Columbia Asia)
Ranks #7 in this list by listed rating (4.5/5 from 98 reviews).
🇮🇳 Manipal Hospital Millers Road (Vikram Hospital)
Ranks #8 in this list by listed rating (4.4/5 from 74 reviews).
🇮🇳 Apollo Hospital, Bannerghatta Road
Ranks #9 in this list by listed rating (4.2/5 from 25 reviews).
🇮🇳 Fortis Hospital, Bannerghatta Road
Ranks #10 in this list by listed rating (4.2/5 from 58 reviews).
How we selected these hospitals
A hospital appears on this page when Gynaecology is among its listed specialties and it is located in Bengaluru, India. Hospitals are not ranked by a proprietary "best" score — the order follows the listed rating (highest first), the same field shown on each hospital's profile.
How to Select the Best Hospital for Ovarian Transposition Surgery in Bengaluru, India?
Choosing the right hospital for ovarian transposition surgery is one of the most important decisions in your treatment journey. A few factors are worth weighing before you decide:
International Accreditation
Look for a hospital with international accreditation such as JCI or NABH — see the accreditation badges shown for each hospital below.
Specialization
Check that the hospital's listed specialties actually include gynaecology rather than only general care.
Capacity and Track Record
Bed count and year established (shown below for each hospital) are a reasonable proxy for scale and operating experience.
Transparent Costs
Ask for an itemised, all-inclusive estimate — hospital charges, room category and stay — before you travel. Our cost calculator (linked below) gives a starting estimate.
Understanding Ovarian Transposition Surgery
Ovarian Transposition (Oophoropexy) is a fertility-preserving gynaecological procedure that surgically repositions one or both ovaries outside the anticipated radiation field prior to pelvic radiotherapy, protecting ovarian function and hormonal reserve in women of reproductive age facing cancer treatment. The procedure carries an ovarian function preservation rate of approximately 70–90% when performed by experienced minimally invasive gynaecological surgeons, making technique and timing critical to outcomes. GAF Healthcare connects international patients with JCI- and NABH-accredited centres in India and JCI- and DHA-accredited hospitals in the UAE, offering end-to-end case coordination, pre-operative oncology review, and post-operative endocrine monitoring at a fraction of Western costs. Hospital Stay: 1–2 days (laparoscopic approach); up to 3–4 days if combined with staging or open surgery • Total Stay in Country (Fit-to-Fly): 1–2 weeks for laparoscopic oophoropexy; 3–4 weeks if open or combined oncological procedure • Success Rate: 70–90% ovarian function preservation rate (endocrine); up to 60–65% live-birth rate when combined with assisted reproduction post-treatment
Clinical Overview
Ovarian Transposition (Oophoropexy) is a surgical fertility-preservation strategy performed in women of reproductive age who are scheduled to receive pelvic or para-aortic radiation therapy for malignancies such as cervical cancer, rectal cancer, Hodgkin lymphoma, or other pelvic tumours. The procedure involves mobilising the ovary on its vascular pedicle — preserving the infundibulopelvic ligament and utero-ovarian ligament blood supply — and anchoring it to the paracolic gutter, the iliac fossa, or above the iliac crest, well outside the anticipated radiation field (typically >3 cm from the field border). Titanium or absorbable surgical clips are placed to mark the transposed ovary, enabling radiologists to exclude it during treatment planning on CT simulation. From a physiological standpoint, the ovaries are exquisitely radiosensitive; doses as low as 2–6 Gy can permanently impair primordial follicle reserve, leading to premature ovarian insufficiency (POI), loss of endogenous oestrogen and progesterone, menopausal symptoms, cardiovascular risk, and infertility. In young women facing curative radiation, the consequences of untreated POI extend decades beyond cancer treatment. Oophoropexy reduces the radiation dose received by the transposed ovary to less than 5–10% of the prescribed pelvic dose, provided the transposition distance is adequate, directly mitigating the long-term endocrine and reproductive sequelae. The current standard of care, as endorsed by the American Society for Reproductive Medicine (ASRM), the European Society of Human Reproduction and Embryology (ESHRE), and the European Society of Gynaecological Oncology (ESGO), is laparoscopic oophoropexy performed 1–2 weeks before the commencement of radiotherapy. The procedure may be performed concurrently with other staging or debulking surgeries under the same anaesthetic to avoid delays to oncological treatment. Robotic-assisted platforms (da Vinci Xi) are increasingly used in high-volume centres in both India and the UAE for precise pedicle dissection and haemostasis, particularly in patients with prior pelvic adhesions or body habitus challenges.
Who is a Candidate?
• Women of reproductive age (typically 18–40 years; considered up to 45 years depending on ovarian reserve) scheduled for curative pelvic or para-aortic external beam radiotherapy or brachytherapy • Diagnoses most commonly warranting the procedure: carcinoma of the cervix (FIGO Stage IB–IVA), carcinoma of the rectum or sigmoid colon, Hodgkin lymphoma with mediastinal or inguinal involvement, Ewing sarcoma of the pelvis, and selected cases of anal or vaginal carcinoma • Patients in whom the ovaries are not directly involved by tumour (confirmed by MRI pelvis with contrast and/or PET-CT) • Adequate ovarian reserve confirmed on baseline transvaginal ultrasound (antral follicle count ≥5–7) and serum Anti-Müllerian Hormone (AMH ≥0.5 ng/mL) • Good performance status (ECOG 0–2) permitting general or regional anaesthesia and laparoscopic insufflation • Required pre-operative diagnostics: MRI pelvis (with and without contrast), PET-CT scan (for lymphoma and cervical cancer staging), transvaginal ultrasound with Doppler, serum AMH, FSH, LH, oestradiol, CA-125 (if ovarian pathology suspected), complete blood count, coagulation profile, and anaesthetic fitness assessment (ECG, chest X-ray, pulmonary function if indicated) • CONTRAINDICATIONS: Direct ovarian metastasis or peritoneal carcinomatosis on imaging; BRCA1/2 germline mutation carriers where prophylactic oophorectomy may be oncologically preferable; hormone-receptor-positive malignancies where residual ovarian function may be contraindicated (e.g., certain endometrial cancers); known severe pelvic adhesive disease precluding safe laparoscopic access; haemodynamic instability or coagulopathy precluding elective surgery; patients in whom radiation field encompasses the entire abdomen (making transposition ineffective)
Treatment Options & Approaches
STANDARD LAPAROSCOPIC OOPHOROPEXY (GOLD STANDARD) The procedure is performed under general anaesthesia via a 3- to 4-port laparoscopic approach. The surgeon identifies the ovary and fallopian tube, dissects the infundibulopelvic ligament to mobilise the ovarian pedicle while preserving the utero-ovarian blood supply, and divides the round ligament and utero-ovarian ligament as needed to gain sufficient pedicle length (typically 8–12 cm of mobilisation required). The ovary is tunnelled retroperitoneally or intraperitoneally and sutured with non-absorbable monofilament (e.g., Prolene 2-0) or absorbable sutures (PDS 2-0) to the peritoneum overlying the paracolic gutter or the anterior abdominal wall, lateral to and above the anterior superior iliac spine. Titanium vascular clips (Hem-o-lok or Liga-clip) are applied at the new ovarian position as radiological markers. Bilateral transposition is performed when both ovaries are to be preserved; unilateral transposition (typically the left ovary, which has a longer pedicle) is performed when one ovary is already compromised. Operative time: 45–90 minutes. ROBOTIC-ASSISTED OOPHOROPEXY (da Vinci Xi / Si PLATFORM) Offered at high-volume centres in India (Apollo, Fortis, Manipal) and the UAE (Cleveland Clinic Abu Dhabi, Mediclinic City Hospital Dubai), robotic assistance provides 10× magnification, EndoWrist articulation, and tremor filtration — critical advantages when dissecting a long vascular pedicle in a narrow pelvis or in patients with prior abdominal surgery or obesity. The robotic approach facilitates a more precise retroperitoneal tunnelling technique, reducing the risk of pedicle torsion. Operative time: 60–120 minutes. Evidence (Morice et al., Huang et al.) supports equivalent or superior ovarian function preservation rates versus conventional laparoscopy in experienced hands. SIMULTANEOUS SURGICAL OOPHOROPEXY (CONCURRENT WITH STAGING/DEBULKING) In patients undergoing laparoscopic or open surgical staging for cervical or rectal cancer, oophoropexy is performed under the same anaesthetic to avoid delaying radiotherapy commencement. This approach requires close multidisciplinary team (MDT) coordination between the gynaecological oncologist, radiation oncologist, and the theatre team for intraoperative radiation field simulation planning. OVARIAN TISSUE CRYOPRESERVATION + OOPHOROPEXY (COMBINED FERTILITY PRESERVATION) For patients at high risk of radiation failure (e.g., large radiation fields, high-dose regimens >20 Gy), oophoropexy may be combined with ovarian cortex cryopreservation or oocyte/embryo cryopreservation (where time before chemotherapy permits controlled ovarian stimulation). This combined strategy, offered at specialist reproductive oncology units in India and the UAE, maximises the probability of future fertility through redundant preservation pathways. POST-PROCEDURE RADIATION PLANNING INTEGRATION Following surgery, CT simulation for radiotherapy planning must explicitly delineate the transposed ovary (identified by the surgical clips) as an organ at risk (OAR). Modern intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) planning systems (Eclipse, Monaco) can then apply dose constraints (typically Dmean <4–5 Gy to the transposed ovary) to reduce scatter and leakage dose. This radiotherapy planning step is as clinically critical as the surgery itself.
Recovery
PHASE 1 — PRE-OPERATIVE EVALUATION (Days 1–7 post-arrival or virtual pre-consultation) • Remote case review by GAF Healthcare's gynaecological oncology panel using uploaded imaging (MRI, PET-CT) and pathology reports • In-country: Repeat or confirmatory MRI pelvis with contrast, transvaginal ultrasound, serum AMH and hormonal profile, PET-CT (if not recently performed) • Multidisciplinary Team (MDT) conference involving gynaecological oncologist, radiation oncologist, reproductive medicine specialist, and (if applicable) medical oncologist • Anaesthetic pre-assessment: ECG, chest X-ray, full blood count, coagulation profile, renal and liver function tests, blood grouping and crossmatch • Patient counselling session: informed consent covering procedure rationale, risks, expected ovarian function preservation rates, and alternative fertility preservation options • Radiation oncology consultation for pre-operative field planning and clip placement strategy PHASE 2 — SURGICAL PROCEDURE (Day 8–10) • Admission the evening before or morning of surgery; nil-by-mouth from midnight • Laparoscopic (or robotic-assisted) oophoropexy under general anaesthesia; operative duration 45–120 minutes depending on approach and complexity • Intraoperative steps: pedicle mobilisation, ovarian transposition to paracolic gutter or above iliac crest, suture fixation, clip marking, laparoscopic port closure • Recovery room: 2–4 hours post-anaesthetic monitoring; vital signs, pain scoring (NRS), and nausea management with ondansetron and low-dose opioid analgesia • Transition to ward: oral fluids commenced within 4–6 hours; mobilisation on the evening of surgery PHASE 3 — IMMEDIATE POST-OPERATIVE PERIOD (Days 1–2 post-surgery / Hospital Stay) • Pain management: paracetamol 1g QDS + ibuprofen 400mg TDS (if no contraindication) as multimodal analgesia; rescue tramadol 50–100mg PRN • Prophylactic LMWH (enoxaparin 40mg SC OD) commenced 12 hours post-operatively for VTE prophylaxis, continued for 7–14 days • Wound inspection: 3–4 laparoscopic port sites (5–12mm); dressing check at 24 hours • Discharge criteria: tolerating oral diet, ambulating independently, NRS pain score ≤3 on oral analgesia, no fever, normal urine output • Discharge with written instructions: wound care, activity restrictions, warning symptoms (fever >38°C, severe pelvic pain, bloating suggesting pedicle torsion) PHASE 4 — EARLY RECOVERY & PRE-FLIGHT PERIOD (Days 3–14) • Outpatient review at Day 7: wound check, suture/clip removal if non-absorbable sutures used, review of any pathology from intraoperative specimens • Radiation oncology review with CT simulation to confirm clip position and plan radiotherapy fields with the transposed ovary as an OAR • Activity: light walking encouraged from Day 1; avoid heavy lifting (>5kg) for 2 weeks; return to desk work at Day 7–10 • Patients undergoing laparoscopic oophoropexy are typically declared fit to fly at Day 10–14, provided no complications PHASE 5 — RADIOTHERAPY COMMENCEMENT & LONG-TERM FOLLOW-UP • External beam radiotherapy (EBRT) or chemoradiation typically commences within 2–4 weeks of surgery once wounds have healed • Ovarian function monitoring post-radiation: serum FSH, LH, oestradiol, and AMH at 3, 6, and 12 months post-treatment • If POI occurs despite transposition (failure rate ~10–30% depending on scatter dose and field size): hormone replacement therapy (HRT) with oestrogen-progesterone combinations initiated under gynaecological endocrinology supervision • Fertility assessment (TVS, AMH, AFC) at 12 months post-radiation if patient wishes to pursue conception via natural means, IVF, or ovarian tissue reimplantation
Risks to be aware of
Ovarian Transposition is generally a safe, minimally invasive procedure, but patients and clinicians must be aware of the following specific and general risks. Ovarian failure despite transposition occurs in 10–30% of cases, most commonly due to scatter radiation dose exceeding the ovarian tolerance threshold, particularly when the radiation field is large (e.g., extended-field or whole-pelvis IMRT), when brachytherapy is added, or when the transposed position is suboptimally distant from the field edge. Ovarian pedicle torsion is a rare but serious early complication (reported incidence 1–3%), presenting as acute-onset pelvic or abdominal pain and requiring urgent laparoscopic detorsion; the risk is mitigated by adequate retroperitoneal fixation and avoiding excessive pedicle tension. Ovarian cyst formation (paratubal or functional cysts) at the transposed site occurs in up to 10–15% of patients, the majority of which are benign and resolve spontaneously, though symptomatic cysts may require aspiration or excision. Clip migration is rare with modern Hem-o-lok or titanium clips but can cause confusion on post-operative imaging if not clearly documented in the operative report. General surgical risks include port-site bleeding or hernia (incidence <1% with correct fascial closure), bowel or bladder injury during dissection in patients with pelvic adhesions (rare, <0.5%), wound infection, and anaesthetic complications stratified by ASA class. Return of ovarian function does not guarantee fertility; patients should be counselled that successful hormone preservation does not equal successful conception, and that radiation-related uterine damage (reduced uterine volume, impaired endometrial receptivity) may independently compromise implantation even if the ovary is functional. In BRCA mutation carriers, residual ovarian tissue post-transposition carries an ongoing risk of ovarian malignancy, and the risk-benefit discussion must involve a clinical geneticist and gynaecological oncologist. Patients should also be informed that ovarian tissue at the transposed site carries a theoretical — though extremely low — risk of harbouring micrometastatic disease in high-risk haematological malignancies, which is a formal contraindication in some centres.
Why GAF Healthcare
GAF Healthcare provides comprehensive end-to-end medical travel coordination for patients travelling to India or the UAE for Ovarian Transposition, managing every logistical detail so patients and their families can focus entirely on treatment and recovery. INDIA — VISA & ENTRY: GAF Healthcare facilitates the e-Medical Visa (e-MV) application for India, which allows a stay of up to 60 days (triple-entry) and is available to citizens of 156+ countries. The e-MV is typically approved within 72 hours. An accompanying e-Medical Attendant Visa (e-MAV) is simultaneously arranged for one family member or caregiver. GAF's India desk provides a formal Medical Visa Support Letter (MVSL) from the treating hospital, which is a mandatory document for the application. UAE — VISA & ENTRY: Citizens of 100+ countries qualify for visa-free entry or visa-on-arrival to the UAE for 30–90 days, covering the typical treatment and recovery period. For patients from countries requiring a pre-arranged visa, GAF Healthcare coordinates a UAE Medical Tourist Visa through the Dubai Health Authority (DHA) or Department of Health Abu Dhabi (DoH) frameworks, including the required medical appointment confirmation letters. AIRPORT & GROUND TRANSFERS: Private ambulance-assisted or wheelchair-enabled airport-to-hospital transfers are arranged for arrival and departure, with a GAF coordinator present to receive patients. All inter-facility transfers (e.g., hospital to imaging centre, hospital to hotel) are managed by a dedicated ground logistics team. DEDICATED PATIENT COORDINATORS & INTERPRETERS: Each patient is assigned a named GAF Healthcare case manager who speaks the patient's primary language (Arabic, Russian, French, Swahili, and others available). Medical interpreters fluent in clinical terminology accompany patients during surgical consultations, MDT meetings, informed consent discussions, and radiotherapy planning sessions. ACCOMMODATION: GAF Healthcare arranges verified accommodation for patients and their attendants within 1–3 km of the treating hospital, ranging from serviced apartments to partner hotels, depending on budget and medical requirements. Accessible rooms, meal-delivery services, and 24-hour on-call support are standard inclusions for all GAF-coordinated stays. TELEMEDICINE FOLLOW-UP: Post-discharge and after the patient has returned home, GAF Healthcare facilitates remote follow-up consultations between the treating gynaecological oncologist or radiation oncologist and the patient's home-country physician, including secure transmission of operative reports, clip-position imaging, and post-radiation hormonal monitoring results.
Common questions about Ovarian Transposition Surgery
What is the cost of Ovarian Transposition (Oophoropexy) in India versus the UAE?
How long do I need to stay in the country before I am fit to fly home after Ovarian Transposition?
What is the success rate of Ovarian Transposition (Oophoropexy)?
Related pages
How GAF Healthcare Assists in Choosing the Best Hospital for Ovarian Transposition Surgery in Bengaluru, India
Discover the Top Hospitals for Ovarian Transposition Surgery in Bengaluru, India
This page lists 10 accredited gynaecology hospitals in Bengaluru, India, so you can compare accreditation, specialties and bed capacity in one place.
Support When You Need It Most
Share your medical reports with us on WhatsApp or email. Our medical team reviews them and comes back with a recommended hospital and treatment plan for your case.
Transparent, All-Inclusive Costs
We provide a single, itemised quote covering hospital charges and stay — no hidden fees, and there's no charge for requesting an estimate. Use our cost calculator alongside this page for a first estimate.
Visa, Travel and Stay Coordination
Once you choose a hospital, we help arrange the medical visa invitation letter, hotel or serviced-apartment booking nearby, airport pickup and transport to your appointments.
Curious what treatment might cost for your case? Use our cost calculator for a personalized estimate.
Frequently asked questions about ovarian transposition surgery in Bengaluru, India
How many gynaecology hospitals are listed in Bengaluru, India?
How do you choose which hospitals to list?
How much does treatment cost in India?
Are there gynaecology hospitals for this in other India cities?
Next Step
Share your medical reports with us and our team will recommend a hospital and treatment plan for ovarian transposition surgery in Bengaluru, India.
Contact us to report an inaccuracy on this page.